[accordionmenu id=”unique7f16138″ accordionmenu=”1960″]
Prof Brendan Buckley has over 30 years’ experience in the medical sector. Brendan was CMO of ICON from 2011 until his retirement earlier this year, having joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and Senior Vice President of Medical Affairs. Brendan has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards for medium to large cardio-metabolic and rare disease clinical studies. Brendan is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and has also been director of the university’s European Center for Clinical Trials in Rare Diseases.
He has been a board member of the Irish Medicines Board and of the European Medical Agency (EMA)’s Scientific Advisory Group for Diabetes and Endocrinology since 2005. He was also a member of the EMA Committee for Orphan Medicinal Products from 2000-2003 and a member of the EMA’s panel of experts. Professor Buckley is also chairman of the Irish Statutory Anti-Doping Agency and is a member of the UK Anti-Doping Scientific Advisory Board. Brendan have been a board member of Breakthrough Cancer Research since 2011 and has recently taken up the position of Chairperson of Fighting Blindness.